Entries |
Document | Title | Date |
20080199495 | Stimulation of thymus for vaccination development - The present disclosure provides methods for enhancing the response of a patient's immune system to vaccination. This is accomplished by reactivating the thymus. Optionally, hematopoietic stem cells, autologous, syngeneic, allogeneic or xenogeneic, are delivered to increase the speed of regeneration of the patient's immune system. In one embodiment the hematopoietic stem cells are CD34 | 08-21-2008 |
20080206280 | VACCINE FOR ACTIVATING HELPER FUNCTION OF CD8+ TCELLS - The invention provides compositions and methods for treating or preventing a target disease in a mammal by induction of memory T cells. The methods comprise (1) administering a sensitizing composition comprising a non-target antigen to a patient; and (2) administering a therapeutic composition comprising a non-target antigen and a target antigen to the patient, wherein the target antigen is associated with the disease, and wherein the therapeutic composition is administered after the sensitizing compositions, at an interval sufficient for induction of memory T cells. The methods can alternatively comprise administering a target antigen along with an inhibitory agent such as an inhibitor of DC apoptosis, an inhibitor of granzyme B, a Granzyme-B-inducible mediator of apoptosis, an inhibitor of perforin, or a perforin-inducible mediator of apoptosis. | 08-28-2008 |
20080226676 | Multivalent avian influenza vaccines and methods - The present invention provides vaccine compositions comprising at least two strains of avian influenza virus, wherein one of the strains has an H5 hemagglutinin subtype and the other strain has an H7 hemagglutinin subtype, and wherein at least one of the strains has an N4 neuraminidase subtype and neither strain has an N1 subtype. Also provided are vaccination methods that utilize the novel vaccine compositions of the invention. The compositions and methods of the present invention provide protection against infection with H5 and H7 influenza strains (e.g., H5N1 and H7N1) while at the same time facilitating the distinction between infected and vaccinated animals. | 09-18-2008 |
20080233148 | Method of Producing Virus - It is intended to provide a safe and efficient method of producing a virus which is free from animal-origin components in the whole process from culturing adhesive cells to producing the virus on an industrial scale by the cell culture. Namely, a method of producing a virus comprising: adhering adhesive cells to a support which has a polypeptide (P) having at least one cell-adhesive minimum amino acid sequence (X) per molecule, and is free from animal-origin components; culturing the adhesive cells in a medium free from animal-origin components; subculturing the cultured adhesive cells using a cell dispersing agent free from animal-origin components; and then inoculating and proliferating a virus in the cells obtained by culturing the adhesive cells. | 09-25-2008 |
20080233149 | Use of Erythropoietin for Enhancing Immune Responses and for Treatment of Lymphoproliferative Disorders - The present invention relates to the use of erythropoietin (EPO) for enhancing immune responses and for the treatment of lymphoproliferative disorders, excluding multiple myeloma. Accordingly to the invention EPO may be administered with a viral or bacterial vaccine. | 09-25-2008 |
20080254067 | Process for the Production of an Influenza Vaccine - The present invention relates to a commercial-scale process for the production of influenza virus or antigens for prophylactic, diagnostic, immunotherapeutic or therapeutic purposes. Particularly, the invention provides a Madin-Darby Canine Kidney (MDCK)-derived, cell line and a cell culture-based process for the production of an influenza vaccine and more particularly, a human vaccine comprising influenza types A and B. | 10-16-2008 |
20080274141 | ANIMAL CELLS AND PROCESSES FOR THE REPLICATION OF INFLUENZA VIRUSES - Animal cells are described which can be infected by influenza viruses and which are adapted to growth in suspension in serum-free medium. Processes for the replication of influenza viruses in cell culture using these cells are furthermore described, as well as vaccines which contain the influenza viruses obtainable by the process or constituents thereof. | 11-06-2008 |
20080286307 | Two-Step Temperature Profile for the Propagation of Viruses - The present invention provides a method for the production of a virus. The method includes providing a host cell that has been infected by the virus and cultivating the infected host cell at two different temperatures. The virus produced by the cultivation steps is subsequently collected. By using the dual temperature cultivation process, high titer and improved purity can be obtained. | 11-20-2008 |
20090010964 | Lipid and Nitrous Oxide Combination as Adjuvant for the Enhancement of the Efficacy of Vaccines - The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered with an adjuvant which adjuvant comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which adjuvant includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5ω3], decosahexaenoic acid [C22: 6ω3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide. | 01-08-2009 |
20090017066 | NOVEL VLPS DERIVED FROM CELLS THAT DO NOT EXPRESS A VIRAL MATRIX OR CORE PROTEIN - The present invention discloses novel influenza virus-like particles (VLPs) that contain chimeric proteins or influenza membrane proteins. The chimeric proteins are derived from fragments of influenza membrane proteins fused to heterologous proteins. The invention includes antigenic formulations and vaccines comprising VLPs of the invention as well as methods of making and administering VLPs to vertebrates, including methods of inducing immunity to infections, such as influenza. | 01-15-2009 |
20090017067 | EMULSION VACCINE COMPOSITIONS COMPRISING ANTIGEN AND ADJUVANT IN THE AQUEOUS PHASE - Emulsion vaccine formulations containing an antigen and an adjuvant in the aqueous phase are used for the vaccination of animals wherein the adjuvant is an acrylic polymer and/or dimethyl dioctadecyl ammonium bromide (DDA). These formulations can be prepared by mixing an aqueous phase containing the antigen and adjuvant with an oil phase in the presence of an emulsifier. | 01-15-2009 |
20090022762 | Polyvalent influenza virus-like particle (VLP) compositions - Polyvalent influenza virus-like particles (VLPs) comprising influenza antigenic polypeptides are described. Also described are compositions comprising these polyvalent VLPs as well as methods of making and using these VLPs. | 01-22-2009 |
20090028904 | Novel cochleate formulations - A process for producing a small-sized, lipid-based cochleate. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca | 01-29-2009 |
20090053264 | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals - The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. | 02-26-2009 |
20090060949 | Flu vaccines and methods of use thereof - This disclosure is directed, inter alia, to polynucleotides, polypeptides, vectors, cells and compositions comprising the same, and their use in affecting viral pathogenesis, in particular for influenza viral infection. | 03-05-2009 |
20090060950 | Method for Producing Viral Vaccines - The present invention provides a method for the manufacture of a preparation comprising virus antigens comprising a) inoculation of cells with infectious virus in a fluid,
| 03-05-2009 |
20090068224 | METHOD TO IDENTIFY POLYPEPTIDE TOLL-LIKE RECEPTOR (TLR) LIGANDS - The present invention provides novel methods to identify polypeptide ligands for Toll-like Receptors (TLRs), such as TLR2, TLR4 and TLR5. The method involves the use of phage display technology in an iterative biopanning procedure. The invention also provides polypeptide TLR ligands identified by the methods of the invention. In preferred embodiments, the polypeptide TLR ligands so identified modulate TLR signaling and thereby regulate the Innate Immune Response. The invention also provides vaccines comprising a polypeptide TLR ligand identified by the methods of the invention and an antigen. The invention also provides methods of modulating TLR signaling using the polypeptide TLR ligands and vaccines of the invention. | 03-12-2009 |
20090074815 | Immunomodulator Compounds as Vaccine Enhancers - A vaccination method utilizes a pharmaceutical combination for enhancing vaccine effectiveness. The method utilizes an immune response-triggering vaccine capable of stimulating production in an immunodefficicent animal of antibodies to a disease-causing agent foreign to the animal. As an adjuvant, a vaccine effectiveness-enhancing amount of an immunomodulator compound is administered, which enhances production and affinity of the antibodies in the animal, in response to the vaccine. | 03-19-2009 |
20090087453 | Virosome particles comprising antigens from influenza virus and hepatitis b virus - The present invention provides a virosome comprising a virosomal membrane comprising at least one lipid and envelope proteins of an enveloped virus and of the virosome and attached to said envelope proteins. Furthermore, the invention provides a vaccine comprising the virosome of the invention and, a method for the production of a virosome of the invention. Moreover, the invention provides a use of a virosome of the invention for the preparation of a vaccine, e.g. for the prevention or alleviation of a disease related to an HBV infection, and a method for the vaccination of a subject. | 04-02-2009 |
20090186049 | METHOD OF TREATING MAGE POSITIVE CANCER - The present invention relates to methods for treating a range of cancers, for example MAGE positive cancers, including, but not limited to melanoma and non-small cell lung cancer (NSCLC). The present invention relates to methods for treating cancer in the adjuvant (eg. post-operative) setting and the active disease setting. | 07-23-2009 |
20090202590 | INFLUENZA VACCINES EXTEMPORANEOUSLY ADSORBED TO ALUMINIUM ADJUVANTS - Antigen and adjuvant components of an adjuvanted influenza vaccine are not mixed during manufacture, but are provided as separate components for extemporaneous mixing at the time of use, for example as a kit comprising (i) an antigen component, comprising an influenza virus antigen; and (ii) an adjuvant component, comprising an aluminium salt. | 08-13-2009 |
20090208531 | ANTIVIRAL AGENTS AND VACCINES AGAINST INFLUENZA - These vaccines target H5N1, H1, H3 and other subtypes of influenza and are designed to elicit neutralizing antibodies, as well as cellular immunity. The DNA vaccines express hemagglutinin (HA) or nucleoprotein (NP) proteins from influenza which are codon optimized and/or contain modifications to protease cleavage sites of HA which affect the normal function of the protein. Adenoviral constructs expressing the same inserts have been engineered for prime boost strategies. Protein-based vaccines based on protein production from insect or mammalian cells using foldon trimerization stabilization domains with or without cleavage sites to assist in purification of such proteins have been developed. Another embodiment of this invention is the work with HA pseudotyped lentiviral vectors which would be used to screen for neutralizing antibodies in patients and to screen for diagnostic and therapeutic antivirals such as monoclonal antibodies. | 08-20-2009 |
20090208532 | Methods Of Producing Influenza Vaccine Compositions - Methods and compositions for the optimization and production of influenza viruses, e.g., ca influenza B strains, in eggs and host cells suitable as influenza vaccines are provided. | 08-20-2009 |
20090220543 | Expression of Proteins in Plants - The invention relates to a method of producing a HPV polypeptides and/or an influenza virus H5 polypeptide in a plant comprising the steps of cloning a HPV gene; and/or an influenza virus H5 gene or nucleic acid encoding their functional equivalents into a vector adapted to target components present in the plant, infiltrating at least a portion of the plant with the vector or transforming plant tissue with the vector so as to transiently express the HPV polypeptides and/or an influenza virus H5 polypeptide, and/or to create a transgenic plant; and recovering the HPV polypeptides and/or an influenza virus H5 polypeptide expressed by the plant. The invention further relates to vectors, transgenic plants or parts thereof and the progeny of such plants used in or which come about as a result of the method. | 09-03-2009 |
20090220544 | ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE - An immunogenic composition comprising (i) a non-virion influenza virus antigen prepared from a virus grown in cell culture; and (ii) an adjuvant. Preferred adjuvants comprise oil-in-water emulsions. | 09-03-2009 |
20090220545 | Adjuvant-Sparing Multi-Dose Influenza Vaccination Regimen - An influenza vaccine is administered by a multi-dose regimen, in which (i) a first dose is administered with an adjuvant and (ii) a later dose is administered either without an adjuvant or with a different adjuvant. Thus the invention provides the benefits of a two-dose regimen without also doubling the supply need for a given adjuvant. | 09-03-2009 |
20090220546 | Adjuvanted influenza vaccines for pediatric use - An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus. | 09-03-2009 |
20090232843 | Identifying and predicting influenza variants and uses thereof - The instant invention provides methods for determining, predicting and characterizing the genetic variability of viruses, in particular, influenza. Accordingly, the invention provides methods for identifying virulent pathogens, genetic mutations within pathogens that are relevant to animal health, and methods and compositions for prophylactic or therapeutic intervention against such pathogens. | 09-17-2009 |
20090232844 | IMMUNOPOTENTIATING COMPOUNDS - The invention provides novel compositions comprising Imidazopyridine compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s). | 09-17-2009 |
20090246225 | Methods of Producing Influenza Vaccine Compositions - Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided. | 10-01-2009 |
20090263421 | CELLULAR VACCINE - The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4 | 10-22-2009 |
20090263422 | INFLUENZA VACCINE - The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol or a tocopherol such as alphatocopherol, and an emulsifying agent. | 10-22-2009 |
20090263423 | Enhancement of an Immune Response by Administration of a Cationic Lipid-DNA Complex (CLDC) - This invention relates to a method for vaccination which is effective for eliciting an enhanced antigen-specific immune response in a mammal, fish or bird. The method is particularly effective for protecting a mammal, fish or bird from a disease including cancer, a disease associated with allergic inflammation, or an infectious disease. Also disclosed are therapeutic compositions useful in such a method. | 10-22-2009 |
20090285854 | FROZEN STOCKPILING OF INFLUENZA VACCINES - A problem with stockpiling influenza vaccines is their short shelf life. Storage volume is another problem. The invention prepares and stockpiles bulk vaccine, and the bulk is stored under frozen conditions. Compared to final vaccine, the higher antigen concentration and absence of packaging materials (boxes, vials, etc.) in the bulk means that the storage space requirements are hugely reduced. A process for preparing an influenza vaccine bulk thus comprises the steps of: (a) preparing bulk vaccine antigen from a source of influenza virus; and (b) storing the bulk vaccine prepared in step (a) under frozen conditions. | 11-19-2009 |
20090291103 | QUALITY CONTROL METHODS FOR OIL-IN-WATER EMULSIONS CONTAINING SQUALENE - Measurements of the squalene content in oil-in-water emulsions can be used as a way of checking for problems during production. In particular, it has been found that a drop in squalene content can indicate that filtration problems occurred. Testing the squalene content in the final lots is easier than investigating the characteristics of the filter, and so a squalene assay simplifies the quality control of oil-in-water emulsions. | 11-26-2009 |
20090297558 | Inactivated Influenza Virus Compositions - The invention provides compositions of inactivated influenza virus that can be used as vaccines and immunological compositions useful for inhibiting, preventing and treating influenza. | 12-03-2009 |
20090297559 | USE OF TIGHT JUNCTION AGONISTS TO FACILITATE PULMONARY DELIVERY OF THERAPEUTIC AGENTS - The present invention provides materials and methods to facilitate the pulmonary delivery of therapeutic agents. In some embodiments, agonists of tight junctions (e.g., zonulin agonists) are used in compositions to facilitate the uptake of therapeutic agents from the pulmonary mucosa. | 12-03-2009 |
20090304742 | INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION ADJUVANT - Influenza vaccines with oil-in-water emulsion adjuvants are known. The amount of emulsion adjuvant required for an influenza vaccine can be reduced, thereby allowing more vaccines to be made from a given amount of emulsion, and/or minimizing the amount of emulsion that has to be produced for a given number of vaccine doses. These vaccines can conveniently be made by mixing (i) an oil-in-water emulsion and (ii) an aqueous preparation of an influenza virus antigen. In one aspect, substantially equal volumes of components (i) and (ii) are used; in another aspect, an excess volume of component (ii) is used. When using substantially equal volumes, component (ii) has a hemagglutinin concentration of more than 60 μg influenza virus strain per ml. Components (i) and (ii) can be presented in kit form. | 12-10-2009 |
20090304743 | Composition and Methods for Immunisation Using CD1D Ligands - The invention relates to immunogenic compositions containing CD1d ligands that induce long-term immunological memory in the absence of booster doses and/or in the absence of multiple priming doses. The invention further relates to immunogenic compositions containing CD1d ligands and antigens from influenza virus, group B | 12-10-2009 |
20090317425 | REFRIGERATOR-TEMPERATURE STABLE INFLUENZA VACCINE COMPOSITIONS - Methods and compositions for the optimization and production of refrigerator-temperature stable virus, e.g., influenza, compositions are provided. Formulations and immunogenic compositions comprising refrigerator-temperature stable virus compositions are provided. | 12-24-2009 |
20090324644 | CHIMERIC VACCINE ANTIGENS AGAINST THE AVIAN INFLUENZA VIRUS - The present invention describes chimeric vaccine antigens against the avian influenza virus (AIV). Said vaccine antigens are based on viral subunits that are coupled to protein molecules that stimulate not only the cellular but also the humoral immune system. The chimeric antigens may be produced in expression systems that guarantee correct three-dimensional folding of the chimeric molecules that constitute the basis of the present invention. The vaccine compositions that contain said chimeric antigens induce a potent, early immune response both in birds and in vaccinated mammals, stimulating high haemagglutinin-inhibiting antibody titres and a potent specific cellular response against the viral antigen. The chimeric antigens, and also the resulting vaccine compositions, are applicable to the field of human and animal health as vaccines for preventive use. | 12-31-2009 |
20090324645 | Production of vaccines - Means and methods for producing mammalian viruses, the method comprising infecting a culture of immortalized human cells with a virus, incubating the culture infected with virus to propagate the virus under conditions that permit growth of the virus, and to form a virus-containing medium, and removing the virus-containing medium. The viruses can be harvested and be used for the production of vaccines. Advantages include that human cells of the present invention can be cultured under defined serum-free conditions and the cells show improved capability for propagating virus. Methods are provided for producing, in cultured human cells, influenza virus and vaccines derived thereof. This method eliminates the necessity of using whole chicken embryos for the production of Influenza vaccines. The method also provides for the continuous or batch-wise removal of culture media. As such, the present invention allows the large-scale continuous production of viruses to a high titer. | 12-31-2009 |
20100008951 | FLU VACCINE ADMIXTURE OF MANNAN AND FLU ANTIGEN - The present invention relates to a vaccine composition comprising a carbohydrate polymer comprising mannose and flu antigen(s) (e.g. whole inactivated influenza virus) in admixture, and a method of immunising a subject comprising the step of administering the vaccine composition to a subject. | 01-14-2010 |
20100008952 | Vaccines for the Rapid Response to Pandemic Avian Influenza - The present invention relates to adenovirus-based vaccines against avian influenza viruses with pandemic potential. The present invention provides replication-defective adenoviral vectors, each having a nucleic acid encoding an influenza A polypeptide. When introduced into a subject, the expressed influenza A polypeptide induces the production of antibodies that bind to influenza. | 01-14-2010 |
20100021499 | CELL-BASED SYSTEMS FOR PRODUCING INFLUENZA VACCINES - The present invention relates to a cell-based method for producing influenza virus vaccines by enriching the population of surface-bound α2,6-sialic acid receptors on a cell surface, such as on a Chinese Hamster Ovary (CHO) cell surface. The host cell therefore presents numerous binding sites to which an influenza virus can bind via its hemagglutinin spike protein and infect the host cell. In contrast to wild-type CHO cells, the surface of the mutated CHO cells of the present invention contains an enriched population of α2,6-sialic acid receptors which makes the inventive CHO cells highly susceptible to viral infection, and therefore safe, effective, and highly efficient cells for rapidly producing influenza vaccines. | 01-28-2010 |
20100028383 | Chemically defined stabiliser - The present invention relates to a stabiliser composition comprising an amino acid, and a sugar wherein all compounds are chemically defined; to a vaccine composition comprising such a stabiliser composition and a biological molecule and/or a micro-organism; to a method for preparing a pharmaceutical composition comprising admixing such a stabiliser composition with a biological molecule and/or a micro-organism; to the use of such a stabiliser composition, and of vaccines prepared therewith. | 02-04-2010 |
20100034852 | METHODS AND COMPOSITIONS FOR PREDICTING AND TREATING DRUG RESISTANT STRAINS OF INFLUENZA VIRUS - The instant invention provides methods for determining, predicting and characterizing the genetic variability of viruses, in particular, influenza. Accordingly, the invention provides methods for identifying virulent pathogens, genetic mutations within pathogens that are relevant to animal health, and methods and compositions for prophylactic or therapeutic intervention against such pathogens. | 02-11-2010 |
20100055130 | STAPHYLOCOCCUS AUREUS PROTEINS AND NUCLEIC ACIDS - The invention provides proteins from | 03-04-2010 |
20100062019 | NEW VACCINE FORMULATIONS - The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof. In one embodiment, the present invention provides for an injectable oil-in-water (O/W) emulsion comprising:
| 03-11-2010 |
20100074920 | PEPTIDE VACCINE FOR INFLUENZA VIRUS - The invention relates to the method for evaluating the potential of a chemical entity, such as an antibody, to bind to a peptide epitope derived from the divalent sialoside binding site of hemagglutinin protein of influenza virus. The invention also provides peptide epitopes 5 for use in the prevention and/or treatment of influenza or for the development of such treatment or vaccine against influenza. | 03-25-2010 |
20100080827 | RECOMBINANT INFLUENZA VIRUSES EXPRESSING TUMOR-ASSOCIATED ANTIGENS AS ANTITUMOR AGENTS - The present invention relates to the engineering of recombinant influenza viruses that express tumor-associated antigens. Expression of tumor-associated antigens by these viruses can be achieved by engineering specific epitopes into influenza virus proteins, or by engineering viral genes that encode a viral protein and the specific antigen as independent polypeptides. Tumor-bearing patients can be immunized with the recombinant influenza viruses alone, or in combination with another treatment, to induce an immune response that leads to tumor reduction. The recombinant viruses can also be used to vaccinate high risk tumor-free patients to prevent tumor formation in vivo. | 04-01-2010 |
20100092514 | METHOD AND DEVICE FOR PRODUCING VACCINE - A method of making a vaccine using animal derived component free (ADCF) cell culture technology, including the steps of attaching ADCF-adapted cells to a microcarrier including an attachment mechanism for attaching filipodia of the cells, the microcarrier being in a culture, growing the cells in ADCF maintenance media, infecting the cells with vaccine media, producing virus within the cells, and harvesting the virus. A vaccine produced by the above method in a pharmaceutically acceptable carrier. A vaccine production structure of ADCF-adapted cells removably attached to microcarrier beads including an attachment mechanism for attaching filipodia of the cells. | 04-15-2010 |
20100098725 | METHODS FOR CULTIVATING CELLS, PROPAGATING AND PURIFYING VIRUSES - The present invention provides novel serum-free cell culture medium and methods for cultivating MDCK cells. In particular, non-tumorigenic MDCK cells. The present invention also provides methods for producing influenza viruses (e.g., particularly cold-adapted, and/or temperature sensitive, and/or attenuated influenza viruses) that eliminate the need for a cell culture medium exchange step. The novel medium and methods are useful to grow influenza viruses, in cell culture to high titer. The present invention further provides purification methods for purifying influenza viruses with high overall recovery of live virus and result in levels of host cell DNA (HCD), host cell protein (HCP) and non-specific endonuclease (e.g., Benzonase), which are below the specifications required by regulatory agencies. The immunogenic compositions can be used to actively immunize subjects or to generate antibodies for a variety of uses, including passive immunization and diagnostic immunoassays. | 04-22-2010 |
20100111999 | PRODUCTION OF POXVIRUSES WITH ADHERENT OR NON ADHERENT AVIAN CELL LINES - The present invention relates to a method for replicating poxviruses such as vaccinia virus comprising the steps of inoculating avian embryonic stem cells with viral particles and culturing said cells in a basal medium until cells lysis occurs and newly produced viral particles are released in said medium. | 05-06-2010 |
20100112000 | NON-TUMORIGENIC MDCK CELL LINE FOR PROPAGATING VIRUSES - The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention. | 05-06-2010 |
20100136053 | INTRADERMAL INFLUENZA VACCINE - The invention relates to virosome-based influenza vaccines for the manufacture of medicaments that are administered intradermally in humans. The invention provides (trivalent) compositions comprising low doses of hemagglutinin (HA) antigen in a virosomal preparation that fulfill the immune response standards with respect to seroconversion rates, GMT-fold increase and protection rates, for use in vaccination set-ups. | 06-03-2010 |
20100158943 | ADMINISTRATION ROUTES FOR PRIMING/BOOSTING WITH INFLUENZA VACCINES - Patients receive a mucosal influenza vaccine and then receive a parenteral influenza vaccine, in that order, typically during different visits to a vaccination center. | 06-24-2010 |
20100158944 | Method for influenza virus protection - A process for the purification of influenza virus or derivative thereof comprising the steps of:
| 06-24-2010 |
20100172937 | ENVELOPED VIRUS NEUTRALIZING COMPOUNDS - Methods for reducing infectivity by providing an enveloped virus neutralizing compound (EVNC) are provided. Methods of preparing a vaccine, vaccine formulations, and methods of immunizing a subject a further provided. Methods of disinfecting a surface are still further provided. In some embodiments, compositions comprising an isolated and purified bioactive EVNC agent are provided. | 07-08-2010 |
20100189745 | Production of Viral Vaccine - The present invention relates, in general, to materials and methods for production of an improved vaccine against influenza virus, wherein the vaccine comprises a reassortant virus having a hemagglutinin gene and a neuraminidase gene from the same influenza A virus subtype or influenza B strain of virus and internal genes from a different influenza A virus subtype or influenza B strain of virus. In one aspect, the HA and NA genes and the internal genes are from a highly pathogenic H5N1 strain of influenza A. | 07-29-2010 |
20100239609 | Formulation of Sugar Solutions for Continuous Ultracentrifugation for Virus Purification - The present invention provides a method for purification of a virus or virus antigen comprising providing a virus preparation and centrifugation of said virus preparation in a gradient of a sugar established by the addition of two or more buffered sugar layers of different concentration. The method leads to higher yields and reduces unwanted aggregation of the virus or virus antigen by increasing the volume of the peak pool. | 09-23-2010 |
20100247572 | VIRUSES ENCODING MUTANT MEMBRANE PROTEIN - A method to prepare viruses with a mutant membrane protein gene, and viruses obtained by the method, are provided. | 09-30-2010 |
20100247573 | Stabilization of Vaccines by Lyophilization - This invention provides pharmaceutical compositions, such as vaccines, and methods of making and using such compositions. | 09-30-2010 |
20100260797 | INFLUENZA COMPOSITION - The present invention relates to influenza vaccine formulations and accelerating primary vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in promoting effective immune responses to various antigens, and to methods of preparation. In particular, the invention relates to two-doses accelerated pandemic or seasonal pandemic primary immunisation regimes with influenza immunogenic compositions comprising an influenza virus or antigenic preparation thereof in combination with an oil-in-water emulsion adjuvant, and to accelerated immunisation regimes. | 10-14-2010 |
20100278860 | SYSTEM AND METHOD FOR IDENTIFYING COMPLEX PATTERNS OF AMINO ACIDS - A method and system are disclosed for identifying and/or locating complex patterns in an amino acid sequence stored in a computer file or database. According to an aspect of the present invention, techniques are provided to facilitate queries of protein databases. For protein descriptions received in response to the queries, embodiments of the present invention may scan the received protein descriptions to identify and locate Replikin patterns. A Replikin pattern is defined to be a sequence of 7 to about 50 amino acids that include the following three (3) characteristics, each of which may be recognized by an embodiment of the present invention: (1) the sequence has at least one lysine residue located six to ten amino acid residues from a second lysine residue; (2) the sequence has at least one histidine residue; and (3) at least 6% of the amino acids in the sequence are lysine residues. | 11-04-2010 |
20100285063 | NOVEL CANINE INFLUENZA VIRUS AND VACCINE THEREFORE - Novel influenza viruses A/Canine/Korea/01/07 (H3N2), A/Canine/Korea/02/07 (H3N2) and A/Canine/Korea/03/07 (H3N2) are disclosed. A vaccine composition comprising at least one of the viruses, a method for preventing or treating diseases resulting from influenza virus infection by administering the vaccine composition, and an assay kit for detecting the viruses are also disclosed. | 11-11-2010 |
20100291146 | METHOD OF ELICITING AN IMMUNE RESPONSE AGAINST PANDEMIC INFLUENZA VIRUS - A method for eliciting or inducing a protective immune response in a subject against a pandemic subtype of influenza virus comprises administering to the subject a composition comprising (i) at least one immunogen of an endemic influenza subtype, and (ii) an immunogen-free immunostimulating complex as adjuvant. | 11-18-2010 |
20100322968 | THERAPEUTIC AGENT FOR CANCER - The present invention provides an adjuvant for cancer antigen peptide vaccines and virus antigen peptides, containing a pertussis vaccine as a primary ingredient. The present invention also provides a therapeutic agent for a cancer or viral infectious disease, and a prophylactic agent for metastasis or recurrence of cancer or onset of virus-induced tumor, containing a cancer antigen peptide or virus antigen peptide and a pertussis vaccine. A pertussis vaccine that can be suitably used is a whole cell body pertussis vaccine. The agents of the present invention can be safely administered in a plurality of doses. | 12-23-2010 |
20100322969 | INFLUENZA B VIRUSES HAVING ALTERATIONS IN THE HEMAGLUTININ POLYPEPTIDE - The present invention encompasses methods of producing influenza B viruses in cell culture. The influenza B viruses may have desirable characteristics, such as enhanced replication in eggs and may be used, for example, in vaccines and in methods of treatment to protect against influenza B virus infection. | 12-23-2010 |
20100322970 | MODIFIED INFLUENZA VIRUS - The present invention provides an influenza B virus M gene with a modification of at least one nucleotide proximate to the N-terminus of the M gene, more specifically at any one of nucleotide positions 265 to 294 of the M gene as well as an influenza B virus comprising said modified M gene. Further, its use for the preparation of a vaccine and methods for preparing said modified influenza virus are disclosed. | 12-23-2010 |
20100330119 | CHROMATOGRAPHY MEDIUM, PREPARATION METHOD OF THE SAME, AND METHOD FOR PRODUCING VIRUS VACCINE USING THE CHROMATOGRAPHY MEDIUM - A Chromatography medium having the properties of high virus adsorption and high fluidity, and a method for producing a virus vaccine using these are provided. The Chromatography medium is formed by binding a sulfated polysaccharide to porous particles having an exclusion limit molecular weight of 6000 Da or less when pure water is used as mobile phase and standard polyethylene glycol is used and an average particle size in the range of 30-200 μm. | 12-30-2010 |
20110014229 | Chimeric flavivirus vectors - The invention provides chimeric flavivirus vectors including foreign peptides inserted into the envelope proteins of the vectors and methods of using these vectors. | 01-20-2011 |
20110027314 | Influenza Vaccines Containing Hemagglutinin and Matrix Proteins - An immunogenic composition comprising influenza virus haemagglutinin and matrix proteins. These may be from influenza viruses grown in cell culture rather than eggs. The matrix protein may be a fragment of a full-length viral matrix protein e.g. a matrix M1 fragment with a molecular weight of less than 2 OkDa. The composition may be a subunit vaccine comprising purified surface glycoproteins. | 02-03-2011 |
20110045022 | VACCINES INCLUDING ANTIGEN FROM FOUR STRAINS OF INFLUENZA VIRUS - Vaccines of the invention include at least four influenza virus strains. In some embodiments, the vaccines are produced in cell culture rather than in eggs. In some embodiments, the vaccines include an adjuvant. In some embodiments, the vaccines are not split or whole virion vaccines, but are live or purified glycoprotein vaccines. In some embodiments, the vaccines contain substantially the same mass of hemagglutinin (HA) for each of the influenza virus strains. In some embodiments, the four strains will include two influenza A virus strains and two influenza B virus strains (‘A-A-B-B’). In other embodiments, the four strains will include three influenza A virus strains and one influenza B virus strain (‘A-A-A-B’). | 02-24-2011 |
20110052633 | MULTI-PHASE EMULSIONS BASED ON AMPHIPHILIC BLOCK COPOLYMERS - An composition comprises (a) a continuous aqueous phase; (b) an oily phase; and (c) an amphiphilic emulsifying system comprising a block copolymer having the formula (A)p-(B)q-(C)r, in which (B)q is a hydrophilic block and (C)r is a hydrophobic block; wherein p, q and r are integers with the proviso that: if p is 0, then A is other than hydroxyl or reactive functional groups and the block copolymer is a diblock copolymer; B and C are each individual repeating) units; if p is >1, then the block copolymer is a triblock copolymer, in which (A)p is a hydrophobic block; the hydrophobic blocks (A)p and (C)r are each homopolymers or heteropolymers; the repeating units A and C are the same or different; and wherein the ratio q/(p+r) is sufficient high so that the hydrophilic-lipophilic balance value of the block copolymer is >10. | 03-03-2011 |
20110059129 | AVIAN INFLUENZA VIRUS VACCINE AND A METHOD FOR PREPARING - The present invention relates to an avian influenza vaccine of plant origin, prepared by transforming a plant with a surface protein of avian influenza virus, hemagglutinin (HA) or neuraminidase (NA), and a method for preparing the same. Further, the present invention relates to an oral vaccine for preventing avian influenza virus, of which mass-production conditions are established, and thus the produced transgenic plant can be more easily, safely, and economically used as a fodder additive. Furthermore, the present invention relates to a reagent for diagnosing avian influenza virus infection, prepared by isolating and purifying a recombinant antigen protein from the transgenic plant. | 03-10-2011 |
20110081378 | COMPOSITION COMPRISING ISCOM PARTICLES AND LIVE MICRO-ORGANISMS - Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle. | 04-07-2011 |
20110104204 | SYSTEMS AND METHODS FOR IDENTIFYING REPLIKIN SCAFFOLDS AND USES OF SAID REPLIKIN SCAFFOLDS - The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease including vaccines and therapeutics for emerging viral diseases and methods of identifying the new class of peptides and related structures. | 05-05-2011 |
20110110978 | HIGH TITER RECOMBINANT INFLUENZA VIRUSES WITH ENHANCED REPLICATION IN VERO CELLS - The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, and genes from vaccine seed virus isolates which include a HA gene segment with a HA2 sequence encoding a HA2 that confers enhanced growth in cells in culture, such as Vero cells. | 05-12-2011 |
20110110979 | METHOD AND VACCINE FOR OPTIMIZING THE SPECIFIC IMMUNE RESPONSES - The present invention relates to a method for treating an infection or disease or lesion, in particular an HPV infection. Furthermore, it relates to a vaccine for treating a Human Papillomavirus (HPV) infection or an associated disease or lesion in a subject. | 05-12-2011 |
20110117127 | ANALYSIS OF DNA BY MEANS OF CAPILLARY ELECTROPHORESIS - The present invention relates to a method for detecting nucleic acids, wherein a sample to be analyzed for the presence of nucleic acids is separated by capillary electrophoresis. The conditions of sample injection and separation allow for an extremely high sensitivity of the method, which can be applied, e.g. for quality control purposes in the determination or the presence, quantity and/or size of genomic DNA contaminants in samples comprising proteins for therapy or vaccination. | 05-19-2011 |
20110129497 | Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes - The instant invention comprises a process of preparing a composition comprising directed sequence polymer (DSP) mixtures that act as epitopes and useful as vaccines, such DSP synthesized according to a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use as a vaccine, preferably for infectious agents that are immune evasive. | 06-02-2011 |
20110142881 | TRANSCUTANEOUS DELIVERY OF THERAPEUTIC AGENTS - The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen. | 06-16-2011 |
20110150925 | CELL-BASED SYSTEMS FOR PRODUCING INFLUENZA VACCINES - The present invention relates to a cell-based method for producing influenza virus vaccines by enriching the population of surface-bound α2,6-sialic acid receptors on a cell surface, such as on a Chinese Hamster Ovary (CHO) cell surface. The host cell therefore presents numerous binding sites to which an influenza virus can bind via its hemagglutinin spike protein and infect the host cell. In contrast to wild-type CHO cells, the surface of the mutated CHO cells of the present invention contains an enriched population of α2,6-sialic acid receptors which makes the inventive CHO cells highly susceptible to viral infection, and therefore safe, effective, and highly efficient cells for rapidly producing influenza vaccines. | 06-23-2011 |
20110150926 | INFLUENZA VACCINES - The invention relates to a method for the treatment or prevention of an influenza virus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a gamma-irradiated influenza virus. | 06-23-2011 |
20110165192 | Methods for producing vaccine adjuvants - An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane. | 07-07-2011 |
20110165193 | Methods for producing vaccine adjuvants - An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane. | 07-07-2011 |
20110171260 | INFLUENZA DNA VACCINATION AND METHODS OF USE THEREOF - The present invention relates to an influenza immunogen that includes one or more DNA constructs encoding at least two divergent influenza HAs, wherein each of such one or more DNA constructs encodes one or more of the at least two divergent influenza HAs. Such an immunogen, when administered to a subject, induces an immune response to a plurality of strains of influenza virus, wherein at least one strain of the plurality of strains does not encode any of the divergent influenza HAs encoded by the immunogen. The divergent influenza HAs can be swine influenza HAs or equine influenza HAs, such as influenza H1 HAs or influenza H3 HAs. The invention also relates to a method to use such an immunogen to induce such an immune response as well as to DNA constructs comprising such divergent influenza HAs. Such an immunogen can provide a heterologous as well as a homologous immune response. Such an immunogen can be used to induce an immune response against evolving influenza virus. | 07-14-2011 |
20110171261 | IMMUNOGENIC COMPOSITION - This invention relates to the use of a CCR4 antagonist as an adjuvant, in particular in an immunogenic composition comprising an antigen which elicits an immune response against a pathogen or tumour. | 07-14-2011 |
20110177121 | Immunogenic Influenza Composition - Novel compositions useful as influenza immunogens are provided. The compositions enable a host response to immunogen sites normally not recognized by a host. | 07-21-2011 |
20110177122 | DNA PRIME/ACTIVATED VACCINE BOOST IMMUNIZATION TO INFLUENZA VIRUS - The present invention relates to a combination of a priming composition and a boosting composition to prime and boost an immune response in a subject whereby the immune response resulting from administration of the priming composition to the subject is capable of being boosted. The priming composition comprises a DNA plasmid that comprises a nucleic acid molecule encoding an influenza virus hemagglutinin (HA) or an epitope-bearing domain thereof. The boosting composition comprises an influenza vaccine. The present invention also relates to a method to use such a combination to vaccinate a subject and to enhance an immune response to an influenza vaccine administered alone. Such a combination can elicit an immune response not only against at least one influenza virus strain from which the priming composition or boosting composition is derived but also to at least one heterologous influenza virus strain. | 07-21-2011 |
20110182938 | INFLUENZA NUCLEIC ACID MOLECULES AND VACCINES MADE THEREFROM - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotypes using the vaccines that are provided. | 07-28-2011 |
20110182939 | Vaccine Adjuvants - The invention provides novel adjuvants and pharmaceutical composition comprising of an adjuvant alone. The invention also provides novel vaccine compositions comprising of an antigen and a novel adjuvant. The novel adjuvant as per present invention is farnesoid-X-receptor (FXR) antagonist. The invention also relates to an adjuvant for variety of antigens. The adjuvant improves antibody production specific to incorporated antigen. The adjuvant also induces cell mediated immune response. | 07-28-2011 |
20110189231 | Compositions Comprising Salmonella Porins and Uses Thereof as Adjuvants and Vaccines - Adjuvants comprising OmpC porin, OmpF porin, or a combination thereof, are provided. The adjuvants can be administered to a subject in combination with antigenic material in order to potentiate the immunogenic effect of the antigenic material. Also provided are products comprising antigenic material in combination with OmpC and/or OmpF, including products comprising a pre-formulated vaccine in combination with OmpC and/or OmpF. Further provided is the use of OmpC and/or OmpF to improve the effect of a pre-formulated vaccine. | 08-04-2011 |
20110195091 | Avian Influenza Virus Antigen, and Booster Immunization Method for Avian Influenza Vaccine in Combination with Mucosal Adjuvant Which is Effective Through Oral Administration - When ELISA antibody titer dropped in chickens intramuscularly inoculated with an oil vaccine, recombinant HA and NP antigens prepared using gene recombinant technology were orally administered in combination with synthetic oligo CpG as a mucosal adjuvant to the chickens. Even when the immune response induced with the oil vaccine was impaired, the antibody titer was re-induced by orally administering the recombinant HA and NP antigens, and synthetic CpG-ODN in combination. | 08-11-2011 |
20110212129 | Method for Producing the Flu Virus - The invention relates to a method for producing flu virus according to which:
| 09-01-2011 |
20110223199 | METHOD FOR PRODUCTION OF pH STABLE ENVELOPED VIRUSES - The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity. | 09-15-2011 |
20110229518 | OPTIMIZED INFLUENZA VACCINES - The invention concerns nucleotides vaccines encoding influenza proteins with few or no glycosylation sites. Since these first introductions of pandemic influenzas the viruses have drifted, accumulating mutations at antigenic sites, but also the N-glycosylation pattern has changed during the drifted years, accumulating N-linked glycosylation sequons that help mask the antigenic sites for recognition by the host immune system. These “naked” initial haemagglutinins induce a broad cross reactivity against widely drifted influenza subtypes. The origin of the DNA or RNA can be both pandemic influenza strains, which codes for proteins which have a naturally low content of glycosylation sites and/or DNA or RNA from non-pandemic influenza strains where the nucleotides have been mutated or changed so it encodes for proteins with less or no glycosylation sites. The invention also discloses DNA or RNA encoding the haemagglutinin (HA) from pandemic influenza A, e.g. the 1918 H1N1 and/or the 1957 H2N2 and/or the 1968 H3N2 influenza A virus, optionally with the Neuraminidase (NA) and/or matrix protein (M) and/or the nucleoprotein (NP) from these pandemic influenza virus included, mixed together with DNA or RNA from non-pandemic influenza A as a vaccine against present day and future influenza A viruses. | 09-22-2011 |
20110236419 | RECOMBINANT CDV COMPOSITIONS AND USES THEREOF - The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said vectors and/or CDV polypeptides, and methods of vaccination against CDV. The invention further provides methods for inducing an immunogenic or protective response against CDV and other canine virus, as well as methods for preventing or treating CDV and other canine virus or disease state(s) caused by CDV and other canine virus. | 09-29-2011 |
20110243987 | INFLUENZA VACCINE - The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent. | 10-06-2011 |
20110250231 | METHOD OF USING PUNICIC ACID TO ENHANCE IMMUNE RESPONSE AND PREVENT METABOLIC DISORDERS - Disclosed is a method of enhancing the immune response of an animal, including mammals and humans, to prevent or ameliorate immunoinflammatory diseases such as Inflammatory Bowel Disease, increase immune system development, maintain or increase CD4 | 10-13-2011 |
20110250232 | DNA-Transfection System for the Generation of Infectious Influenza Virus - The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly. | 10-13-2011 |
20110262482 | ANTI-VIRAL COMPOUNDS - Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway. | 10-27-2011 |
20110280907 | METHOD AND SYSTEM FOR BUILDING A PHYLOGENY FROM GENETIC SEQUENCES AND USING THE SAME FOR RECOMMENDATION OF VACCINE STRAIN CANDIDATES FOR THE INFLUENZA VIRUS - A computer-implemented method and a computer system for identifying a phylogenetic tree from a plurality of biological sequences is provided. Each biological sequence is associated with a sampling date. First, the plurality of biological sequences is aligned and a distance matrix is obtained. Then, a subset of these sequences without any duplicated sequences is selected and a directed graph representation of the subset of biological sequences is generated based the associated sampling dates. Then, a minimum spanning tree is computed from the weighted directed graph representation. Then, in an iterative procedure, the sequences of unsampled evolutionary intermediates are inferred from mutation patterns that reflect the difference in sequence between the nodes in the minimum spanning tree. The new sequences are added with associated time stamps to the sequence set. Then, sets of identical sequences are removed. Then, an optimum branching is recomputed. This step is repeated until no new intermediates are found. In the final step, the sequences that have been set aside in the initializing step are added to the plurality of sequences derived in the update step. From this plurality of sequences an optimum branching is computed and identified as the phylogenetic tree. Amino acid changes repeatedly occurring on the internal branches of the obtained tree can be used to identify sequences and associated viral isolates suitable as vaccine strains for the following influenza season. | 11-17-2011 |
20110287054 | MULTIVALENT ADJUVANTED INFLUENZA VIRUS COMPOSITIONS - The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to multivalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from at least two influenza virus strains, at least one strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant. | 11-24-2011 |
20110293658 | USE OF INKT OR TLR AGONISTS FOR PROTECTING AGAINST OR TREATING A DISEASE SUCH AS ACUTE INFECTION OR CANCER - A method of protecting a mammalian subject against, or treating, a disease, wherein the mammalian subject has elevated numbers and/or activities of MDSC comprising administering to the subject a pharmaceutically acceptable amount of an iNKT agonist, such as alpha galactosylceramide or an analogue thereof, or a TLR agonist, or a combination thereof. | 12-01-2011 |
20110293659 | METHOD FOR THE ORAL/MUCOSAL VACCINATION BY MEANS OF RECOMBINANT YEASTS - Recombinant yeast cells are produced which are used for vaccination, among other uses for the oral vaccination by feeding. | 12-01-2011 |
20110293660 | NOVEL METHOD - The present invention relates to a method for purifying a virus, or a viral antigen thereof, comprising at least the following steps: a) obtaining a fluid comprising the virus, or a viral antigen thereof, and b) purifying the fluid by at least one density gradient ultracentrifugation step, wherein the ratio of the amount of virus, or viral antigen thereof, present in the fluid over the density gradient volume is less than 1, less than 0.8, less than 0.6 and less than 0.4. | 12-01-2011 |
20120014991 | NOVEL, NON-ANTIGENIC, MUCOSAL ADJUVANT FORMULATION WHICH MODULATES THE EFFECTS OF SUBSTANCES, INCLUDING VACCINE ANTIGENS, IN CONTACT WITH MUCOSAL BODY SURFACES - Adjuvant for mucosal vaccines which modulates the effects of substances, including vaccine antigens in contact with mucosal body surfaces. | 01-19-2012 |
20120034266 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSE BY A NUTRACEUTICAL ANTIOXIDANT - The present invention provides a new means of restoring the immune system in aging and immunocompromised individuals using an antioxidant nutraceutical. The nutraceutical stimulates the aging immune system through the Nrf2 master gene regulatory pathway. The invention is based in part on the discovery that the Nrf2 has antioxidant and immune restorative activity. The nutraceutical improves function of both the innate and adaptive immune systems. | 02-09-2012 |
20120039933 | METHODS FOR ONE-DOSE INTRADERMAL DELIVERY FOR NON-LIVE TRIVALENT INFLUENZA VACCINE - The invention relates to methods for one-dose influenza vaccine for intradermal delivery of a trivalent, non-live influenza antigen preparation, particularly a split influenza preparation. | 02-16-2012 |
20120064116 | INFLUENZA NUCLEIC ACID MOLECULES AND VACCINES MADE THEREFROM - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotypes using the vaccines that are provided. | 03-15-2012 |
20120087944 | ORAL VACCINE FAST-DISSOLVING DOSAGE FORM USING STARCH - A fast-dissolving dosage form (FDDF) for the delivery of a vaccine is prepared using a formulation containing a starch, optionally, along with at least one additional matrix forming agent, preferably, a combination of gelatin and mannitol, wherein an immune response is induced in a patient in need thereof. | 04-12-2012 |
20120093859 | INFLUENZA VACCINE REGIMENS FOR PANDEMIC-ASSOCIATED STRAINS - In contrast to known regimens where pandemic-associated antigens are given 3-4 weeks apart for immunisation, according to the invention two doses of a pandemic-associated antigen are administered to a human 1 week apart, 2 weeks apart or 6 weeks apart. Thus the invention provides a method for immunizing a human, comprising steps of: (a) administering to the human a first vaccine comprising antigen from a pandemic-associated influenza virus strain; and then 1/2/6 week(s) later, (b) administering to the same human a second influenza vaccine comprising antigen from the pandemic-associated influenza virus strain. | 04-19-2012 |
20120128716 | Vaccine Compositions - Vaccine compositions, useful for eliciting an immune response in subjects which is protective against influenza type A virus, comprise influenza type A virus antigen and a bacterial sialidase. An intranasal vaccine against highly pathogenic subtype H5N1 virus, for use in the treatment of poultry, preferably comprises inactivated H5N1 antigen, sialidase from | 05-24-2012 |
20120128717 | INFLUENZA VIRUS VACCINE COMPOSITION AND METHODS OF USE - The present invention is directed to compositions and methods for enhancing the immune response of a human in need of protection against influenza virus (IV) infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof, or a protein encoded thereby. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount. | 05-24-2012 |
20120148622 | Live Attenuated Influenza Virus Vaccines Comprising Microrna Response Elements - The invention is directed to novel live attenuated influenza virus (LAIV) vaccines comprising one or more microRNA (miRNA) Response Element(s) (MRE) within an influenza virus genome. The MREs useful for the present invention can be derived from any miRNA which is highly expressed in influenza-targeted cells of an animal in need of vaccination but are not expressed or are expressed at very low levels in species (e.g., embryonated chicken eggs) or cell lines used for a large-scale vaccine production. This allows efficient vaccine production but renders the vaccine virus susceptible to attenuation in the influenza-targeted cells of vaccinated animals expressing a cognate miRNA. | 06-14-2012 |
20120156241 | RESCUE OF INFLUENZA VIRUS - The invention relates to the field of influenza vaccine production. Influenza vaccines have been produced in embryonated hens' eggs for over 50 years, but recently there have been considerable efforts to develop cell culture systems for vaccine production. In one embodiment, the invention provides a nucleic acid comprising an influenza gene segment and a bacteriophage polymerase promoter or a complementary strand of said nucleic acid, and a cell comprising such a nucleic acid capable of producing desired influenza virus. In another embodiment, the invention provides a composition comprising a cell or material derived from a cell according to the invention and a virus or material derived from a viral particle according to the invention. | 06-21-2012 |
20120156242 | An Antigenic Peptide Derived From Influenza Virus And A Method For Selecting Anti-Influenza Virus Antibody - Antigenic peptides are provided that can be used to induce global neutralizing antibodies, or antibodies reactive against a wide range of influenza A virus strains. The antigenic peptide can correspond to SEQ ID NO: 34 (EKEVLVLWG), SEQ ID NO: 2 (KFDKLYIWG), SEQ ID NO: 71(QEDLLVLWG), SEQ ID NO: 51 (EGRINYYWTLLEP), SEQ ID NO: 3 (PSRISIYWTIVKP), and/or SEQ ID NO: 82 (SGRMEFFWTILKP). | 06-21-2012 |
20120164174 | ADJUVANT COMPOSITION CONTAINING POLY-GAMMA-GLUTAMIC ACID-CHITOSAN NANOPARTICLES - The present invention relates to an adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles and a vaccine composition containing the adjuvant composition, and more particularly to an adjuvant composition containing nanoparticles prepared by ionic bonding between poly-gamma-glutamic acid having ensured safety and chitosan, and a vaccine composition containing the poly-gamma-glutamic acid-chitosan nanoparticles and an antigen. The adjuvant containing the poly-gamma-glutamic acid-chitosan nanoparticles has little or no toxicity and side effects and is added to human or animal vaccines for the prevention and treatment of viral and bacterial infections and cancers to increase the production of antibodies. | 06-28-2012 |
20120164175 | NOVEL INFLUENZA VIRUS - The present invention provides a novel influenza virus wherein both the NS and the PB1 gene segments are modified and wherein the PB1-F2 open reading frame is modified by introduction of at least one stop codon. Specifically, the influenza virus is lacking functional NS1 and PB1-F2 proteins. | 06-28-2012 |
20120171245 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 07-05-2012 |
20120177685 | PEPTIDE VACCINES AGAINST GROUP A STREPTOCOCCI - This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A | 07-12-2012 |
20120201851 | GENERIC ASSAY FOR DETECTION OF INFLUENZA VIRUSES - The invention relates to generic methods for the detection and quantification of influenza viruses. These may uses a reverse transcription (RT-PCR) real time (q-PCR) assay which amplifies a conserved region within influenza A or B strains. The assays allow the quantification of influenza virus RNA molecules or whole virus particles, irrespective of the particular virus strain (e.g. human, avian, swine flu). The methods are particularly applicable as diagnostic assays or in the monitoring of vaccine production processes. | 08-09-2012 |
20120207785 | PROCESS FOR PREPARING AN INFLUENZA SEED VIRUS FOR VACCINE MANUFACTURE - The present invention relates to the use of avian cell lines for the preparation of seed influenza vaccines, and to vaccines made therefrom. | 08-16-2012 |
20120213818 | COMBINATION THERAPY FOR IMMUNOSTIMULATION - The present invention relates to a method for immunostimulation in a mammal which comprises | 08-23-2012 |
20120219584 | PROTECTION AGAINST PANDEMIC AND SEASONAL STRAINS OF INFLUENZA - Immunogens and compositions are provided that encode a protein comprising an influenza A subtype H1 hemagglutinin glycan-shielded receptor binding domain A (RBD A) region and at least one influenza A subtype H1 hemagglutinin antigenic site wherein the antigenic site is not within the RBD-A region. Also provided are immunogens and compositions that encode an immunogenic protein comprising at least one epitope of the RBD-A region of a pandemic influenza A subtype H1 hemagglutinin antigen. Also provided are such proteins, nucleic acids that encode such proteins, and antibodies against such proteins. Also provided are methods to use such immunogens and compositions to elicit a neutralizing antibody immune response against influenza A subtype H1 virus. | 08-30-2012 |
20120244183 | INFLUENZA VIRUSES AND USES THEREOF - Described herein are chimeric influenza virus gene segments and nucleic acid sequences encoding such chimeric influenza virus gene segments. A chimeric influenza virus gene segment described herein comprises packaging signals found in the non-coding and coding regions of one type of influenza virus gene segment and an open reading frame of a different type of influenza virus gene segment or fragment thereof. Also described herein are recombinant influenza viruses comprising two or more chimeric influenza virus gene segments and the use of such viruses in the prevention and/or treatment of influenza virus disease. | 09-27-2012 |
20120244184 | MODIFIED PEPTIDE VACCINE DERIVED FROM INFLUENZA M2 - A modified peptide derived from matrix protein 2 (hereinafter also referred to as “M2”), one of surface layer proteins of influenza virus, and a method for utilization of the modified peptide are provided. A peptide (hereinafter also referred to as “M2eC peptide”) that is made up by inserting cysteine residue(s) into a peptide (hereinafter also referred to as “M2e”) consisting of 23 amino acid residues of from positions No. 2 to No. 24 of M2 in influenza virus type A, a fusion protein consisting of said modified peptide and a polypeptide, an influenza vaccine comprising said modified peptide or said fusion protein as an active ingredient, a device which can be delivered into the body comprising said influenza vaccine, a nucleic acid fragment consisting of a nucleotide sequence encoding the amino acid sequence of said modified peptide or said fusion protein, an expression vector in which said nucleic acid fragment is incorporated, a host in which said expression vector is introduced, and an antibody that has a protective effect against influenza virus. | 09-27-2012 |
20120244185 | IMMUNIZATION STRATEGY TO PREVENT H1N1 INFECTION - The invention provides chimeric viral expression vectors and method of use for providing an immune response against H1N1 influenza. The compositions of the invention can be used as vaccines for H1N1 strains. Advantages include rapid development and availability once a strain is isolated, and effective oral or mucosal administration. | 09-27-2012 |
20120258136 | METHODS FOR CULTIVATING CELLS, PROPAGATING AND PURIFYING VIRUSES - The present invention provides novel serum-free cell culture medium and methods for cultivating MDCK cells. In particular, non-tumorigenic MDCK cells. The present invention also provides methods for producing influenza viruses (e.g., particularly cold-adapted, and/or temperature sensitive, and/or attenuated influenza viruses) that eliminate the need for a cell culture medium exchange step. The novel medium and methods are useful to grow influenza viruses, in cell culture to high titer. The present invention further provides purification methods for purifying influenza viruses with high overall recovery of live virus and result in levels of host cell DNA (HCD), host cell protein (HCP) and non-specific endonuclease (e.g., Benzonase), which are below the specifications required by regulatory agencies. The immunogenic compositions can be used to actively immunize subjects or to generate antibodies for a variety of uses, including passive immunization and diagnostic immunoassays. | 10-11-2012 |
20120282294 | REFRIGERATOR-TEMPERATURE STABLE INFLUENZA VACCINE COMPOSITIONS - Methods and compositions for the optimization and production of refrigerator-temperature stable virus, e.g., influenza, compositions are provided. Formulations and immunogenic compositions comprising refrigerator-temperature stable virus compositions are provided. | 11-08-2012 |
20120328654 | MULTI-PHASE EMULSIONS BASED ON AMPHIPHILIC BLOCK COPOLYMERS - A method for enhancing a body's response to an immunogen is disclosed. The method comprises immunizing a subject in need thereof a vaccine composition in a water-in-oil (W/O/W) emulsion that comprises (a) an antigen; and (b) an adjuvant composition in a W/O/W emulsion. The adjuvant composition comprises: (i) a continuous aqueous phase comprising H | 12-27-2012 |
20130052222 | INFLUENZA NUCLEIC ACID MOLECULES AND VACCINES MADE THEREFROM - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotpyes using the vaccines that are provided. | 02-28-2013 |
20130089570 | ORAL VACCINE COMPROMISING AN ANTIGEN AND A TOLL-LIKE RECEPTOR AGONIST - The present invention provides an immunogenic composition comprising one or more antigens and a Toll-like receptor (TLR) agonist in an orally (e.g. sublingually) administered composition. | 04-11-2013 |
20130095134 | STABILIZED VIRUS LIKE PARTICLES HAVING ENHANCED MUCOSAL IMMUNOGENICITY - This disclosure relates to compositions and methods for inducing immune response. Specifically, the disclosure relates to a composition comprising a subunit antigen stabilized by a polysaccharide-containing plant extract, in which the antigen consists of virus-like particles that have enhanced mucosal immuno-genicity as a result of the stabilization. | 04-18-2013 |
20130122045 | Cross-Protective Influenza Vaccine - The invention relates to a method for preventing or treating an influenza virus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a gamma-irradiated influenza virus, wherein the virus comprises an A/Port Chalmers/1/73 (A/PC) strain backbone of PB2, PB1, PA, NP, M1, M2 and NEP proteins. | 05-16-2013 |
20130142825 | METHOD OF PREVENTING AND TREATING INFLAMMATORY DISEASES AND DISORDERS WITH ABSCISIC ACID - The present invention relates to the use of a therapeutically effective amount of abscisic acid (ABA) or its analogs to treat or prevent inflammation induced by exposure to lipopolysaccharide (LPS) or respiratory inflammation. The invention also relates to methods and composition for enhancing vaccine efficacy using ABA. | 06-06-2013 |
20130149337 | METHOD OF CONTROLLING ADMINISTRATION OF CANCER ANTIGEN - The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to a method of controlling administration of cancer antigen to a subject by providing bi-specific T cells that express a viral antigen T cell receptor and a cancer antigen-specific chimeric receptors and triggering their activation by also administering antigen-presenting T-cells which express viral antigen. These bi-specific T cell clones are a source of effector cells that persist in vivo in response to stimulation with viral antigen, leading to long-term function after their transfer to patients with cancer and autoimmune diseases. | 06-13-2013 |
20130189304 | PRESERVATION OF BIOACTIVE MATERIALS BY FREEZE DRIED FOAM - This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes. | 07-25-2013 |
20130189305 | METHODS OF PRODUCING INFLENZA VACCINE COMPOSITIONS - Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided. | 07-25-2013 |
20130195915 | Influenza C Virus and Vaccine - A novel influenza C virus with only low homology to any influenza C virus previously characterized. Challenge studies show that the virus can infect pigs and be transmitted between pigs. Additionally, influenza C is commonly thought of as a human pathogen and serological studies have been performed, looking at the incidence of antibodies against this virus in both pigs and humans. Approximately 10% of pigs and 30% of humans have antibodies to this virus. Additional experimental data show that the virus can infect and transmit in ferrets (a surrogate for human infection studies). In a third aspect, the present invention is the partial genome of this novel influenza C virus. In another aspect, the present invention is a method of detection in animals of this novel influenza C virus. | 08-01-2013 |
20130195916 | System and Method for Identifying Complex Patterns of Amino Acids - A method and system are disclosed for identifying and/or locating complex patterns in an amino acid sequence stored in a computer file or database. According to an aspect of the present invention, techniques are provided to facilitate queries of protein databases. For protein descriptions received in response to the queries, embodiments of the present invention may scan the received protein descriptions to identify and locate Replikin patterns. A Replikin pattern is defined to be a sequence of 7 to about 50 amino acids that include the following three (3) characteristics, each of which may be recognized by an embodiment of the present invention: (1) the sequence has at least one lysine residue located six to ten amino acid residues from a second lysine residue; (2) the sequence has at least one histidine residue; and (3) at least 6% of the amino acids in the sequence are lysine residues. | 08-01-2013 |
20130195917 | IMMUNOADJUVANT - The invention thus relates to a method for boosting the efficiency of a vaccine by co-administering a probiotic bacterium such as | 08-01-2013 |
20130209510 | METHODS FOR PREPARING SQUALENE - An improved method for preparing squalene from a squalene-containing composition, said method comprising the steps of (a) a purification distillation carried out at a temperature T | 08-15-2013 |
20130209511 | Recombinant Poxviral Vectors Expressing both Rabies and OX40 Proteins, and Vaccines Made Therefrom - The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. In a particular example, the invention provides vectors encoding a Rabies G immunogenic polypeptide and a canine OX40L genetic adjuvant, which vectors elicit strong immune responses in canine against rabies virus | 08-15-2013 |
20130209512 | UNIVERSAL INFLUENZA A VACCINES - Universal flu vaccines are disclosed. The vaccines induce broad and sustained protection against a wide range of influenza A viruses, reduce the need for annual vaccination campaigns with vaccines based upon viral strains predicted to be the predominant circulating strains, and ameliorate the threat of future pandemics that can potentially kill millions. | 08-15-2013 |
20130216574 | KIT PROVIDING MULTIPLE UNMET THERAPEUTIC EFFECTS - The present invention discloses a unique kit for providing a combinational therapeutic product comprising a medical device and a pharmaceutical composition to treat mammal diseases. The medical device is to meet these unmet needs of cleansing out these harmful substances, such as viruses, multiple drug resistant bacteria, fungi, pollen, dusts, or excessive mucus. The pharmaceutical composition adds the required functions of anti-inflammatory, anti-allergy, anti-cancer, promoting membrane healing or immunomodulating, to have the added effect of the medical device. The method of using the combinational product is also disclosed. The new product can be used to prevent and treat a variety of diseases, such as common cold, drug resistant influenza, sinusitis, post nasal drip, virus-triggered asthma, or chronic obstructive pulmonary disease. In addition, the new kit and the process of use are safe and cost effective. | 08-22-2013 |
20130230556 | HERPESVIRUS OF TURKEYS VECTORED VACCINE AGAINST AVIAN INFLUENZA IN POULTRY - The present application applies to the field of veterinary vaccines, in particular of vaccines for poultry against avian influenza. The vaccine is based on a recombinant viral vector expressing the haemagglutinin protein of an influenza virus, wherein the vector is herpes virus of turkeys (HVT) and the haemagglutinin gene is driven by a glycoprotein B gene promoter from a mammalian herpesvirus. A vaccine comprising this HVT+HA vector can be used to induce a protective immune response against avian influenza in poultry, and to reduce the spread of AIV. The invention also relates to methods, uses, and vaccines involving the HVT+HA vector. | 09-05-2013 |
20130243817 | VACCINE COMPOSITIONS - Present invention relates to vaccine formulations and adjuvants for use in e.g. compositions, thereby avoiding the phenomenon of Bell's palsy in a frequency above the natural occurance. | 09-19-2013 |
20130259898 | Vaccine Composition - Disclosed are compositions and the use of the compositions for protection against pathogens comprising an isolated internal pathogenic protein, a TLR agonist and an aluminum salt. | 10-03-2013 |
20130273104 | Adjuvanted Influenza Vaccines for Pediatric Use - An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus. | 10-17-2013 |
20130280296 | DNA VACCINE AGAINST MULTITYPES OF AVIAN INFLUENZA VIRUSES AND INFLUENZA VIRUS-LIKE PARTICLES COMPRISING ADJUVANT-FUSED M2 PROTEIN - A DNA vaccine comprising hyperglycosylated mutant HA gene, which is derived from avian influenza virus, is provided. A DNA vaccine composition comprising: (a) the DNA vaccine; and (b) a booster is also provided. An influenza virus-like particle comprising adjuvant-fused M2 protein is further provided. A method for eliciting an immune response against a plurality of avian influenza virus subtypes in a subject, comprising delivering the DNA vaccine or the DNA vaccine composition to tissue of the subject is also provided | 10-24-2013 |
20130280297 | USE OF TOXOPLASMA GENE PRODUCTS TO PREVENT OR TREAT MICROBIAL INFECTIONS - The invention provides immunomodulatory proteins, e.g., useful to prevent, inhibit or treat microbial infection. | 10-24-2013 |
20130280298 | Immunogenic Affinity-Conjugated Antigen Systems Based on Papaya Mosaic Virus and Uses Thereof - An affinity-conjugated antigen system (ACAS) comprising one or more antigens conjugated via a plurality of affinity moieties to a papaya mosaic virus (PapMV) or virus-like particle (VLP) derived from the coat protein of PapMV is provided. The affinity moieties are molecules or compounds that are capable of specifically binding to the antigen(s) of interest and which can be attached, for example by chemical or genetic means, to the coat protein of the PapMV or PapMV VLP. The ACAS can optionally further comprise one or more additional antigens, which may be the same as, or different to, the conjugated antigen(s) comprised by the ACAS. Also provided are immunogenic compositions, including vaccines, comprising an ACAS. The immunogenic compositions are useful in the treatment, including prevention, of various diseases and disorders for which a humoral and/or cellular response in the animal is required. | 10-24-2013 |
20130287811 | Method for Producing Viral Vaccines - The present invention provides a method for the manufacture of a preparation comprising virus antigens comprising
| 10-31-2013 |
20130315953 | GENERIC ASSAYS FOR DETECTION OF MAMALIAN REOVIRUS - The invention relates to generic methods for the detection and quantification of mammalian reoviruses. These may uses a reverse transcription (RT-PCR) real time (q-PCR) assay which amplifies a conserved region within all MRV types. The assays allow the quantification of MRV RNA molecules, irrespective of the particular virus type (e.g. MRV-1, MRV-2). The methods are particularly applicable in the monitoring of vaccine production processes. | 11-28-2013 |
20130315954 | METHOD FOR IMPROVING THE PRODUCTION OF INFLUENZA VIRUSES AND VACCINE SEEDS - The present invention relates to a method for improving the production of an influenza virus, and in particular influenza vaccine seeds, or a vaccine directed against an influenza virus, characterized in that the production is carried out in the presence of an inhibitor of the interaction between the Mdm2 protein and the p53 protein. | 11-28-2013 |
20130323280 | METHODS FOR PREPARING VESICLES AND FORMULATIONS PRODUCED THEREFROM - The present disclosure provides methods for preparing vesicles. In one aspect, the methods involve providing a molten mixture of vesicle-forming lipids and adding the molten mixture of vesicle-forming lipids to an aqueous solution comprising an antigen such that antigen-containing vesicles are formed, wherein in the step of adding the molten mixture of vesicle forming lipids is at a temperature of less than 120° C. In another aspect, the methods involve providing a molten mixture of vesicle-forming lipids and adding an aqueous solution comprising an antigen to the molten mixture of vesicle-forming lipids such that antigen-containing vesicles are formed, wherein the resulting mixture is placed under temperature-controlled conditions of less than 60° C. In yet another aspect, the methods involve providing a solution of vesicle forming lipids and adding the solution of vesicle-forming lipids to an aqueous solution comprising an antigen by injection such that antigen-containing vesicles are formed. | 12-05-2013 |
20130344106 | Methods and Compositions for Improving Immune Response by a Nutraceutical Antioxidant - The present invention provides a new means of restoring the immune system in aging and immunocompromised individuals using an antioxidant nutraceutical. The nutraceutical stimulates the aging immune system through the Nrf2 master gene regulatory pathway. The invention is based in part on the discovery that the Nrf2 has antioxidant and immune restorative activity. The nutraceutical improves function of both the innate and adaptive immune systems. | 12-26-2013 |
20140004149 | Immunogenic Influenza Composition | 01-02-2014 |
20140004150 | Vaccine Injection, Preparation Method and Use Thereof | 01-02-2014 |
20140017279 | ADJUVANT NANOEMULSIONS WITH CRYSTALLISATION INHIBITORS - High loading of lipophilic pharmacological agents (in particular, lipophilic immunopotentiators) in oil-in-water emulsions can result in crystallisation of the lipophilic agent. To overcome this problem the invention uses an oil-in-water emulsion in combination with a crystallisation inhibitor, and this combination provides emulsions which can be loaded with high levels of lipophilic pharmacological agents. | 01-16-2014 |
20140023681 | Attenuated Swine Influenza Vaccines and Methods of Making and Use Thereof - This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof. The attenuated strains are engineered to encode HA proteins having additional glycosylation sites, relative to the HA proteins encoded by the corresponding virulent parental viruses. Advantageously, the attenuated influenza strains may be administered | 01-23-2014 |
20140056940 | NOVEL ADJUVANT COMPOSITIONS - This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals. | 02-27-2014 |
20140093537 | IMMUNOGENIC COMPOSITIONS COMPRISING NANOEMULSION AND METHODS OF ADMINISTERING THE SAME - The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides immunogenic nanoemulsion compositions and methods of administering the same (e.g., via a heterologous prime/boost protocol (e.g., utilizing the same nanoemulsion in each the prime and boost administrations)) to induce immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against an environmental pathogen)). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications. | 04-03-2014 |
20140093538 | Method for Priming of T Cells - The present invention relates to an in vitro method for priming T cells suitable for administration to a patient having a viral infection. The invention is also directed to the composition obtained by the method and uses thereof. | 04-03-2014 |
20140127262 | REFRIGERATOR-TEMPERATURE STABLE INFLUENZA VACCINE COMPOSITIONS - Methods and compositions for the optimization and production of refrigerator-temperature stable virus, e.g., influenza, compositions are provided. Formulations and immunogenic compositions comprising refrigerator-temperature stable virus compositions are provided. | 05-08-2014 |
20140127263 | AUGMENTATION OF TITER FOR VACCINATION IN ANIMALS - The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine. | 05-08-2014 |
20140141041 | RAPID AND PROLONGED IMMUNOLOGIC-THERAPEUTIC - The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT). | 05-22-2014 |
20140178427 | TOTAL POLYSACCHARIDES OF RADIX ISATIDIS AND THEIR FRACTIONS, AND USES THEREOF AS VACCINE ADJUVANTS - The present invention pertains to medicinal technical field, relates to a Radix isatidis total polysaccharide and fractions thereof and their uses as vaccine adjuvant. Specifically, it relates to a Radix isatidis total polysaccharide as well as neutral polysaccharide fraction and acidic polysaccharide fraction extracted from Chinese medicinal material Radix isatidis, and to their uses as vaccine adjuvant or uses in manufacture of vaccine composition. The present invention further relates to a vaccine adjuvant and vaccine preparation comprising the above Radix isatidis total polysaccharide or polysaccharide fraction, a method for preparing antibody, and a method for immunization or inoculation. The Radix isatidis total polysaccharide as well as neutral polysaccharide fraction and acidic polysaccharide fraction of the present invention all can be used as adjuvant for attenuated vaccines, protein vaccines, DNA vaccines or polypeptide vaccines. | 06-26-2014 |
20140178428 | QUALITY CONTROL METHODS FOR OIL-IN-WATER EMULSIONS CONTAINING SQUALENE - Measurements of the squalene content in oil-in-water emulsions can be used as a way of checking for problems during production. In particular, it has been found that a drop in squalene content can indicate that filtration problems occurred. Testing the squalene content in the final lots is easier than investigating the characteristics of the filter, and so a squalene assay simplifies the quality control of oil-in-water emulsions. | 06-26-2014 |
20140178429 | Vaccines Including Antigen From Four Strains of Influenza Virus - Vaccines of the invention include at least four influenza virus strains. In some embodiments, the vaccines are produced in cell culture rather than in eggs. In some embodiments, the vaccines include an adjuvant. In some embodiments, the vaccines are not split or whole virion vaccines, but are live or purified glycoprotein vaccines. In some embodiments, the vaccines contain substantially the same mass of hemagglutinin (HA) for each of the influenza virus strains. In some embodiments, the four strains will include two influenza A virus strains and two influenza B virus strains (‘A-A-B-B’). In other embodiments, the four strains will include three influenza A virus strains and one influenza B virus strain (‘A-A-A-B’). | 06-26-2014 |
20140186396 | METHODS FOR STABILIZING INFLUENZA ANTIGEN ENVELOPED VIRUS-BASED VIRUS-LIKE PARTICLE SOLUTIONS - Methods of stabilizing solutions with enveloped virus-based virus-like particles containing an influenza antigen and such stabilized solutions are described. | 07-03-2014 |
20140234372 | NOVEL VLPS DERIVED FROM CELLS THAT DO NOT EXPRESS A VIRAL MATRIX OR CORE PROTEIN - The present invention discloses novel influenza virus-like particles (VLPs) that contain chimeric proteins or influenza membrane proteins. The chimeric proteins are derived from fragments of influenza membrane proteins fused to heterologous proteins. The invention includes antigenic formulations and vaccines comprising VLPs of the invention as well as methods of making and administering VLPs to vertebrates, including methods of inducing immunity to infections, such as influenza. | 08-21-2014 |
20140242112 | NOVEL VACCINE - The present invention provides an immunogenic composition comprising one or more antigens and a Toll-like receptor (TLR) 7 agonist in an orally (e.g. sublingually) administered composition. | 08-28-2014 |
20140286992 | INFLUENZA VIRUS-LIKE PARTICLE (VLP) COMPOSITIONS - Influenza virus-like particles (VLPs) comprising influenza antigenic polypeptides are described. Also described are compositions comprising these VLPs as well as methods of making and using these VLPs. | 09-25-2014 |
20140294894 | TRANSCUTANEOUS DELIVERY OF THERAPEUTIC AGENTS - The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen. | 10-02-2014 |
20140308313 | COMPOSITIONS AND METHODS FOR IMMUNISATION USING CD1D LIGANDS - The invention relates to immunogenic compositions containing CD1d ligands that induce long-term immunological memory in the absence of booster doses and/or in the absence of multiple priming doses. The invention further relates to immunogenic compositions containing CD1d ligands and antigens from influenza virus, group B | 10-16-2014 |
20140363467 | AVIAN INDUCED PLURIPOTENT STEM CELLS AND THEIR USE - The present invention relates to the production of avian induced pluripotent stem cells from non-pluripotent somatic cells, including embryonic fibroblasts and adult somatic cells. In this method, avian (including quail or chicken) somatic cells are reprogrammed into a state closely resembling embryonic stem cells including the expression of key stem cell markers alkaline phosphatase, etc. by transfecting/transducing the non-stem cells with genes (preferably using a non-integrating vector as otherwise described herein or alternatively an integrating vector, such a lentiviral vector, retroviral vector or inducible lentiviral vector, among others) which express at least nanog, Lin28 and cMyc. In preferred aspects of the invention, the transfected/transduced vectors express nanog, Lin28, cMyc, Oct 4 (POU5F1 or PouV), SOX2 and KLF4. The induced stem cells which are produced contribute to all 3 germ layers, the trophectoderm and in certain aspects, the gonad in chimeric offspring. | 12-11-2014 |
20140377308 | METHOD FOR PRODUCTION OF pH STABLE ENVELOPED VIRUSES - The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity. | 12-25-2014 |
20150010595 | VACCINES COMPRISING AN IMMUNOSTIMULATORY PEPTIDE AND AN IMMUNOSTIMULATORY OLIGODEOXYNUCLEIC ACID MOLECULE - The invention refers to an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R | 01-08-2015 |
20150017205 | HIGH TITER RECOMBINANT INFLUENZA VIRUSES WITH ENHANCED REPLICATION IN MDCK OR VERO CELLS OR EGGS - The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, that confer enhanced growth in cells in culture, such as MDCK cells, or in eggs. | 01-15-2015 |
20150056249 | INFLUENZA VACCINES - The present invention relates to influenza vaccine compositions and vaccination schemes for immunizing against influenza disease, in particular it relates to immunogenic compositions comprising an antigen or a antigenic preparation from a first influenza virus strain and an oil-in-water emulsion adjuvant for use in inducing a immune response against at least one second influenza virus strain wherein said second influenza virus strain is from a different type or from a different subtype than said first influenza virus strain. | 02-26-2015 |
20150086587 | VACCINE ADJUVANT - Oil-based adjuvant emulsions, immunogenic compositions, and methods of using the same to elicit immunological responses in a subject are provided. The oil-based adjuvants comprise a plant-derived surfactant, such as gum arabic, an aqueous component, and an oil. The adjuvant emulsions can be used to potentiate the immunological effects of active agents, including antigens derived from various pathogens and/or toxins. Immunogenic compositions comprising the adjuvant emulsions and various active agents are also provided, along with vaccine systems for therapeutic or prophylactic treatment of a subject using these adjuvants. | 03-26-2015 |
20150118264 | PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGEN - The present invention is directed to a pharmaceutical composition including (e.g. for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases. | 04-30-2015 |
20150140036 | LOW, IMMUNE ENHANCING, DOSE MTOR INHIBITORS AND USES THEREOF - The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, e.g., with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001. | 05-21-2015 |
20150297710 | EMULSION VACCINE COMPOSITIONS COMPRISING ANTIGEN AND ADJUVANT IN THE AQUEOUS PHASE - Emulsion vaccine formulations containing an antigen and an adjuvant in the aqueous phase are used for the vaccination of animals wherein the adjuvant is an acrylic polymer and/or dimethyl dioctadecyl ammonium bromide (DDA). These formulations can be prepared by mixing an aqueous phase containing the antigen and adjuvant with an oil phase in the presence of an emulsifier. | 10-22-2015 |
20150299667 | INFLUENZA VIRUS AND TYPE 1 DIABETES - Type 1 diabetes mellitus is characterized by loss of pancreatic insulin-producing beta cells, resulting in insulin deficiency. The usual cause of this beta cell loss is autoimmune destruction. The inventors provide the first evidence of a causal link between influenza virus infection and the development of type 1 diabetes and/or pancreatitis. This causal link between infection and type 1 diabetes and/or pancreatitis provides various therapeutic, prophylactic and diagnostic opportunities. | 10-22-2015 |
20150313989 | Immunogenic Influenza Composition - Novel compositions useful as influenza immunogens are provided. The compositions enable a host response to immunogen sites normally not recognized by a host. | 11-05-2015 |
20150329895 | Methods of Determining Cell Mediated Response - The invention relates to the use of one of more biomarkers, such as granzyme B, to determine an immune response, such as a cell-mediated immune response, of a subject to an immunostimulatory composition. The invention also relates to methods of treating a subject determined to develop a poor immune response to an immunostimulatory composition. Further, the invention relates to kits for use in practicing methods of the invention. | 11-19-2015 |
20150335737 | ADJUVANT COMPOSITIONS AND METHODS OF USE - This disclosure provides adjuvant compositions that are capable of modulating the immune response in a subject. These adjuvant compositions may also be used enhance the immunogenicity of antigens. Also provided are methods of making the adjuvant compositions as well as methods of using the adjuvant compositions. | 11-26-2015 |
20150359863 | VACCINE COMPRISING AN OIL IN WATER EMULSION - The present invention provides an immunogenic composition comprising an antigen or antigen composition and an adjuvant composition comprising an oil in water emulsion, wherein said oil in water emulsion comprises 0.5-10 mg metabolisable oil, 0.5-11 mg tocol and 0.1-4 mg emulsifying agent, per human dose. | 12-17-2015 |
20150366962 | SYNTHETIC TLR4 AND TLR7 LIGANDS AS VACCINE ADJUVANTS - This disclosure relates to compositions and methods useful to augment an immune response and methods and compositions for inducing immunogenicity to influenza antigens. | 12-24-2015 |
20160002606 | METHOD FOR INFLUENZA VIRUS PURIFICATION - A process for the purification of influenza virus or derivative thereof comprising the steps of:
| 01-07-2016 |
20160015800 | NASAL INFLUENZA VACCINE COMPOSITION - The invention relates to an influenza vaccine composition for spray-administration to nasal mucosa, which comprises an inactivated whole influenza virion and a gel base material comprising carboxy vinyl polymer, which is characterized by not comprising an adjuvant. | 01-21-2016 |
20160017334 | 5'-TRIPHOSPHATE OLIGORIBONUCLEOTIDES - Disclosed herein are synthetic oligoribonucleotides that form hairpin loop structures. The oligoribonucleotides can be used in the treatment of viral infection including prophylactic treatments. The oligoribonucleotides can also be used as adjuvants. | 01-21-2016 |
20160022807 | METHODS AND COMPOSITIONS FOR IN VIVO IMMUNE STIMULATION AND ANTIGEN PRODUCTION - Disclosed are compositions and methods comprising a vector and a reverse genetics competent unit. The vector may comprise baculovirus expression vectors, bacmids, vaccinia virus and synthetic vectors and the reverse genetics competent unit may comprise pathogenic units necessary for producing pathogens de novo from a nucleotide-based vector. In certain embodiments, the reverse genetics competent unit comprises pathogenic units necessary for producing pathogens de novo from a nucleotide-based vector for influenza virus. | 01-28-2016 |
20160024477 | ATTENUATED INFLUENZA VIRUSES AND VACCINES - This invention provides highly attenuated influenza viruses and vaccines. The attenuated viruses and vaccines proliferate well and have high safety factors. The attenuated viruses providing protective immunity from challenge by virus of the same subtype, as well as cross protection against heterologous viruses. | 01-28-2016 |
20160024525 | REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS - Expression of a transgene is driven in a host cell using a pol I promoter which is not endogenous to an organism from the same taxonomic order from which the host cell is derived. | 01-28-2016 |
20160038585 | INFLUENZA VIRUS REASSORTMENT - New influenza donor strains for the production of reassortant influenza B viruses are provided. | 02-11-2016 |
20160045580 | IDENTIFICATION OF CD8+ T CELLS THAT ARE CD161HI AND/OR IL18R(ALPHA)HI AND HAVE RAPID DRUG EFFLUX CAPACITY - This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8 | 02-18-2016 |
20160076006 | THERMOSENSITIVE MUTANTS OF INFLUENZA VIRUSES - The invention relates to thermosensitive mutants of influenza viruses, containing at least one mutation localised in a flexible region of a protein of said virus, such as especially the region of the sub-unit PA of the viral polymerase corresponding to the region 197-225 of the sub-unit PA of influenza A. These viruses can be especially used for preparing attenuated living vaccines. | 03-17-2016 |
20160114034 | COMPOSITIONS COMPRISING ISCOM PARTICLES AND LIVE MICRO-ORGANISMS - Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle. | 04-28-2016 |
20160120973 | Attenuated Swine Influenza Vaccines and Methods of Making and Use Thereof - This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof. The attenuated strains are engineered to encode HA proteins having additional glycosylation sites, relative to the HA proteins encoded by the corresponding virulent parental viruses. Advantageously, the attenuated influenza strains may be administered | 05-05-2016 |
20160120982 | VACCINE STABILIZER - Disclosed herein is a formulation capable of enhancing thermostability and shelf-life of a biological product, the formulation comprising: a tertiary amine N-oxide or a derivative thereof represented by the formulae: | 05-05-2016 |
20160136250 | Hydrophobic Preparations - The present invention relates to preparations of substances in hydrophobic solvents in which they would not normally be soluble and to processes for obtaining these preparations. In particular, the invention relates to preparations of hydrophilic species in hydrophobic solvents such as oils. The use of these preparations as vaccines and in pharmaceutical compositions is also described. | 05-19-2016 |
20160136260 | ATTENUATED INFLUENZA VACCINES AND USES THEREOF - Provided herein are attenuated influenza viruses and methods of making attenuated influenza viruses. | 05-19-2016 |
20160158341 | PREPARATION OF INFLUENZA VIRUS VACCINE ANTIGENS - A number of improvements for preparing vaccine antigens from disintegrated influenza viruses are disclosed. A splitting step can be followed by detergent exchange. Splitting can take place in the presence of a buffer with a higher ionic strength and/or in the presence of phosphate buffer. | 06-09-2016 |
20160175425 | METHOD FOR RAPIDLY DESIGNING PHARMACEUTICAL PREPARATIONS FOR PREVENTING VIRAL INFECTION | 06-23-2016 |
20160184423 | METHODS FOR THE PREVENTION OF AGGREGATION OF VIRAL COMPONENTS - The present invention relates to a method for prevention and/or reduction of aggregation of viral components. | 06-30-2016 |
20160184424 | INTRANASAL VACCINATION DOSAGE REGIMEN - The present invention relates in a first aspect to a vaccine kit comprising a) a first vaccine component comprising i) a first set of one or more containers, each container containing a vaccine composition for intranasal administration, b) optionally a second vaccine component comprising a second set of one or more containers, each container containing a vaccine composition for intranasal administration, and c) optionally instructions for use, wherein each container of the first and second set of containers contains a volume of the vaccine composition from about 5 microliter to about 400 microliter. The present invention also relates to: An administration regimen for intranasal administration of a vaccine composition for use in immunizing a human. A device for use in administration of vaccine compositions. The use of: a) a first vaccine component comprising i) a first set of one or more containers, each container containing a vaccine composition for intranasal administration, b) optionally a second vaccine component comprising a second set of one or more containers, each container containing a vaccine composition for intranasal administration, wherein each container of the first and second set of containers contains a total volume of the vaccine composition from about 5 microliter to about 400 microliter for immunizing a human. The use of: a) a first vaccine component comprising i) a first set of one or more containers, each container containing a vaccine composition for intranasal administration, b) optionally a second vaccine component comprising a second set of one or more containers, each container containing a vaccine composition for intranasal administration, wherein each container of the first and second set of containers contains a total volume of the vaccine composition from about 5 microliter to about 400 microliter for the preparation of a vaccine for intranasally immunizing a human. The method of treating a person in need of a vaccination. The vaccine formulated for intranasal administering. | 06-30-2016 |
20160193324 | METHODS OF IMMUNIZATION WITH VARICELLA ZOSTER VIRUS ANTIGEN | 07-07-2016 |
20160250168 | ESTERS OF SHORT CHAINS FATTY ACIDS FOR USE IN THE TREATMENT OF IMMUNOGENIC DISORDERS | 09-01-2016 |
20190142929 | INFLUENZA VACCINE REGIMENS FOR PANDEMIC ASSOCIATED STRAINS | 05-16-2019 |